Imdusiran sodium clinical trials
Also written AB-729.
A product of Imdusiran; its studies count on that page too.
How each study uses imdusiran sodium is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the imdusiran sodium studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AB-729
- 3
Studies by the year they started
4 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2021 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Arbutus Biopharma Corporation (1) · University of Maryland, Baltimore (1) · Assembly Biosciences (1) · Antios Therapeutics, Inc (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Imdusiran
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test imdusiran sodium.
- Dec 2026Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis BPhase 2 · University of Maryland, Baltimore
Studies
Open first, then newest update. How each study uses imdusiran sodium is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis BRecruitingPhase 2University of Maryland, BaltimoreNCT06154278Written as Imdusiran (AB-729)
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionCompletedPhase 2Arbutus Biopharma CorporationNCT04980482Written as AB-729
- A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B InfectionTerminatedPhase 2Assembly BiosciencesNCT04820686Written as AB-729
- A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus CoinfectionTerminatedPhase 2Antios Therapeutics, IncNCT04847440Written as AB-729
Codes
What other systems call imdusiran sodium · ClinicalTrials.gg INT016805
- UNII (FDA) HX4CRZ94FCIMDUSIRAN SODIUMOne source FDA
- NCI Thesaurus C203141Imdusiran SodiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HX4CRZ94FC | IMDUSIRAN SODIUM | One source FDA |
| NCI Thesaurus | C203141 | Imdusiran Sodium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.